Home Tags Tissue factor

Tag: tissue factor

Supplemental Biologics License Application for Tisotumab Vedotin Accepted for FDA Priority...

The U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for tisotumab vedotin (Tivdak®; Genmab and Pfizer) for the treatment of patients with recurrent or metastatic cervical cancer.

Initial Dose-Escalation of First-in-Human Phase 1 JEWEL-101 Trial Evaluating XB002 in...

An ongoing, phase 1 dose-escalation study investigating XB002, Exelixis’ next-generation tissue factor-targeting antibody-drug conjugate (ADC) for the treatment of patients with advanced solid tumors, has shown promising results.
Featured Image: Genmab's bioreactor laboratory. Photo Courtesy: 2020 Genmab.

Promising Preliminary Data on Tisotumab Vedotin in Patients with Head and...

Preliminary data from the innovaTV 207 global, open-label, multicenter phase 2 trial of tisotumab vedotin (Tivdak®; Seagen and Genmab) as a monotherapy in patients...

MRG004A Enters Clinical Development for the Treatment of Solid Tumors

MRG004A, an antibody-drug conjugate targeting human tissue factor to treat solid tumors, has entered clinical trials in the United States.  The investigational agent, being...
Research associate at Genmab, Cell culturing. Photo courtesy: 2020 Genmab/Tuala Hjarnø and Torkil Stavdal

US FDA Grants Accelerated Approval to Tisotumab Vedotin for Recurrent or Metastatic...

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tisotumab vedotin-tftv (Tivdak™; Seagen/GenMab; previously known as HuMax®-TF-ADC), a first-in-class and only approved...
Featured Image: Genmab's bioreactor laboratory. Photo Courtesy: 2020 Genmab.

U.S. FDA Accepts Priority Review of Tisotumab Vedotin BLA for Patients...

Each year more than 13,500 women in the United States are diagnosed with invasive cervical cancer and approximately 4,200 will die of the disease....

ESMO 2020: Study Shows Meaningful Clinical Activity with Tisotumab Vedotin ...

Tisotumab vedotin, an investigational agent is being developed by Seattle Genetics and Genmab, shows meaningful clinical activity as monotherapy in patients with previously treated...

Zymeworks Signs Licensing Agreement with Iconic Therapeutics

Canada-based Zymeworks, a clinical-stage biopharmaceutical company, has entered into a licensing agreement that grants Iconic Therapeutics non-exclusive rights to the company's proprietary ZymeLink™ antibody-drug...

Phase II Trial of Tisotumab Vedotin in Advanced Cervical Cancer Provides...

Genmab and Seattle Genetics confirmed their decision to start a Phase II study of tisotumab vedotin in patients with recurrent and/or metastatic cervical cancer....
pancreatic cancer cells

Fab’-installed Polymeric Micelles Significantly Improve Efficient Drug Delivery to Solid Tumors

To enhance the efficacy of unconjugated antibodies, researchers have optimized their antitumor activity by conjugating them with radionuclides, toxins, or cytotoxic drugs. The choice...

X